Pharmacare Ethical Report

This report will be looking at ethical considerations in marketing, product safety, and intellectual property. It will examine and analyze the way PharmaCare conducts business to see if they are ethical in the ways they deal with direct marketing of products to patients instead of going through the right channels. I am going to analyze if bypassing the FDA to sell the AD23 directly to customers is legal and ethical and if they broke any law.
I will also examine if the FDA could have done something to stop PharmaCare and the proxy they used to avoid the law and avoid prosecution. Many companies do unethical activities to avoid the laws and hide away from prosecution. In this report, I will also look at John’s action of stealing the memo and serving at a whistleblower on the effects of AD23 on the patients. Can that be considered as stealing of intellectual property and what kind of protection will be
The FDA has the power to stop the production of the AD23 and bring the management of the company to justice for the death of over 200 people of cardiac arrest.
There is a need to give the FDA more powers when it comes to control of compounding pharmacies. This will take care of the existing loopholes currently being exploited by companies such as PharmaCare.
(4) Analyze the manner in which PharmaCare used U.S. law to protect its own intellectual property and if John has any claim to being the true “inventor” of AD23. Suggest at least three (3) ways the company could compensate John for the use of his intellectual property

PharmaCare cleverly used the U.S law to protect its own interest by the establishment if the a compounding pharmacy because they know that the FDA do not have a need to approve the compounding drugs. By establishing a proxy company to do the selling of the AD23 directly